GENinCode Plc has entered into a commercial agreement with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® Polygenic Risk Score test, which is designed to help predict and prevent coronary heart disease.
The partnership targets Mexico’s large cardiovascular disease market, estimated to be worth around US$4.3 billion, where heart disease remains the leading cause of death. Under the agreement, Sohin Genetics will market and promote the test through its network of hospitals and clinics, supported by GENinCode’s SITAB international reporting platform.
The move marks an expansion of GENinCode’s footprint in Latin America and follows its recent collaboration with AMPAC, further strengthening the company’s position in the rapidly growing cardiovascular disease prevention market.
Matthew Walls, GENinCode Chief Executive Officer said; “We are delighted to announce this latest distribution agreement with Sohin Genetics to sell CARDIO inCode-Score in Mexico. The collaboration will extend our reach into this growing cardiovascular disease market and allow us to consider other tests for distribution in the region.”
